二肽基肽酶-4 抑制剂的多效性心血管作用。
The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors.
机构信息
Department of Medicine, Section of Diabetes and Metabolic Diseases, University of Padova, Padova, Italy.
出版信息
Br J Clin Pharmacol. 2018 Aug;84(8):1686-1695. doi: 10.1111/bcp.13611. Epub 2018 Jun 3.
Abstract
Patients with Type 2 diabetes have an excess risk for cardiovascular disease. One of the several approaches, included in the guidelines for the management of Type 2 diabetes, is based on dipeptidyl peptidase 4 (DPP-4; also termed CD26) inhibitors, also called gliptins. Gliptins inhibit the degradation of glucagon-like peptide-1 (GLP-1): this effect is associated with increased circulating insulin-to-glucagon ratio, and a consequent reduction of HbA1c. In addition to incretin hormones, there are several proteins that may be affected by DPP-4 and its inhibition: among these some are relevant for the cardiovascular system homeostasis such as SDF-1α and its receptor CXCR4, brain natriuretic peptides, neuropeptide Y and peptide YY. In this review, we will discuss the pathophysiological relevance of gliptin pleiotropism and its translational potential.
摘要
2 型糖尿病患者患心血管疾病的风险过高。几种方法之一，包括 2 型糖尿病管理指南，基于二肽基肽酶 4（DPP-4；也称为 CD26）抑制剂，也称为gliptins。Gliptins 抑制胰高血糖素样肽-1（GLP-1）的降解：这种作用与循环胰岛素与胰高血糖素比值增加有关，从而导致 HbA1c 降低。除了肠降血糖素之外，还有几种可能受 DPP-4 及其抑制影响的蛋白质：其中一些与心血管系统稳态有关，例如 SDF-1α及其受体 CXCR4、脑利钠肽、神经肽 Y 和肽 YY。在这篇综述中，我们将讨论 gliptin 多效性的病理生理学相关性及其转化潜力。
相似文献
1
The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors.
Br J Clin Pharmacol. 2018 Aug;84(8):1686-1695. doi: 10.1111/bcp.13611. Epub 2018 Jun 3.
2
The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway.
Cardiovasc Diabetol. 2018 May 19;17(1):60. doi: 10.1186/s12933-018-0702-3.
3
Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials.
Cell Signal. 2013 Sep;25(9):1799-803. doi: 10.1016/j.cellsig.2013.05.009. Epub 2013 May 22.
4
Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):479-86. doi: 10.1016/j.beem.2009.03.004.
5
Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.
Vascul Pharmacol. 2011 Jul-Sep;55(1-3):10-6. doi: 10.1016/j.vph.2011.05.001. Epub 2011 May 31.
6
An Update on Dipeptidyl Peptidase-IV Inhibiting Peptides.
Curr Protein Pept Sci. 2024;25(4):267-285. doi: 10.2174/0113892037287976231212104607.
7
Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines.
Cardiovasc Diabetol. 2018 Jan 8;17(1):9. doi: 10.1186/s12933-017-0648-x.
8
Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases.
Vascul Pharmacol. 2018 Oct;109:17-26. doi: 10.1016/j.vph.2018.05.010. Epub 2018 Jun 4.
9
Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus.
Am J Ther. 2008 Sep-Oct;15(5):484-91. doi: 10.1097/MJT.0b013e3180ed42dc.
10
Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes.
Peptides. 2018 Feb;100:150-157. doi: 10.1016/j.peptides.2017.10.011.
引用本文的文献
1
Dipeptidyl Peptidase (DPP)-4 Inhibitors and Pituitary Adenylate Cyclase-Activating Polypeptide, a DPP-4 Substrate, Extend Neurite Outgrowth of Mouse Dorsal Root Ganglia Neurons: A Promising Approach in Diabetic Polyneuropathy Treatment.
Int J Mol Sci. 2024 Aug 15;25(16):8881. doi: 10.3390/ijms25168881.
2
Effects of dipeptidyl peptidase 4 inhibition on the endothelial control of the vascular tone.
Am J Physiol Cell Physiol. 2023 Oct 1;325(4):C972-C980. doi: 10.1152/ajpcell.00246.2023. Epub 2023 Aug 29.
3
Non-Specific Inhibition of Dipeptidyl Peptidases 8/9 by Dipeptidyl Peptidase 4 Inhibitors Negatively Affects Mesenchymal Stem Cell Differentiation.
J Clin Med. 2023 Jul 12;12(14):4632. doi: 10.3390/jcm12144632.
4
Dipeptidyl peptidase-4 inhibitors reduced long-term cardiovascular risk in diabetic patients after percutaneous coronary intervention via insulin-like growth factor-1 axis.
Sci Rep. 2022 Mar 24;12(1):5129. doi: 10.1038/s41598-022-09059-2.
5
Influence of Dipeptidyl Peptidase-4 (DPP4) on Mesenchymal Stem-Cell (MSC) Biology: Implications for Regenerative Medicine - Review.
Stem Cell Rev Rep. 2022 Jan;18(1):56-76. doi: 10.1007/s12015-021-10285-w. Epub 2021 Oct 22.
6
SARS-CoV-2 and diabetes: A potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19.
Metabol Open. 2021 Dec;12:100134. doi: 10.1016/j.metop.2021.100134. Epub 2021 Oct 13.
7
Potential for Gut Peptide-Based Therapy in Postprandial Hypotension.
Nutrients. 2021 Aug 17;13(8):2826. doi: 10.3390/nu13082826.
8
Managing diabetes in diabetic patients with COVID: where do we start from?
Acta Diabetol. 2021 Nov;58(11):1441-1450. doi: 10.1007/s00592-021-01739-1. Epub 2021 Jun 25.
9
Type 2 Diabetes Mellitus and COVID-19: A Narrative Review.
Front Endocrinol (Lausanne). 2021 Mar 31;12:609470. doi: 10.3389/fendo.2021.609470. eCollection 2021.
10
DPP-4 Inhibitors Have Different Effects on Endothelial Low-Grade Inflammation and on the M1-M2 Macrophage Polarization Under Hyperglycemic Conditions.
Diabetes Metab Syndr Obes. 2021 Apr 6;14:1519-1531. doi: 10.2147/DMSO.S302621. eCollection 2021.
本文引用的文献
1
DPP-4 Inhibitors Improve Diabetic Wound Healing via Direct and Indirect Promotion of Epithelial-Mesenchymal Transition and Reduction of Scarring.
Diabetes. 2018 Mar;67(3):518-531. doi: 10.2337/db17-0934. Epub 2017 Dec 18.
2
Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial.
JAMA Cardiol. 2018 Feb 1;3(2):155-163. doi: 10.1001/jamacardio.2017.4228.
3
Diabetes mellitus as a poor mobilizer condition.
Blood Rev. 2018 May;32(3):184-191. doi: 10.1016/j.blre.2017.11.002. Epub 2017 Nov 8.
4
Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial.
JACC Heart Fail. 2018 Jan;6(1):8-17. doi: 10.1016/j.jchf.2017.08.004. Epub 2017 Oct 11.
5
Diabetes Mellitus and Heart Failure.
Am J Cardiol. 2017 Jul 1;120(1S):S37-S47. doi: 10.1016/j.amjcard.2017.05.014. Epub 2017 May 30.
6
Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α in Patients With Type 2 Diabetes.
Diabetes Care. 2017 Aug;40(8):1073-1081. doi: 10.2337/dc17-0061. Epub 2017 May 26.
7
Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.
Cardiovasc Diabetol. 2017 May 11;16(1):63. doi: 10.1186/s12933-017-0546-2.
8
Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis.
CMAJ Open. 2017 Feb 24;5(1):E152-E177. doi: 10.9778/cmajo.20160058. eCollection 2017 Jan-Mar.
9
Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry.
Diabetes Obes Metab. 2017 Oct;19(10):1416-1424. doi: 10.1111/dom.12979. Epub 2017 May 31.
10
DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes.
Cardiovasc Diabetol. 2017 Feb 10;16(1):22. doi: 10.1186/s12933-017-0507-9.
Zotero 插件